SLC5A1 and type 2 diabetes mellitus: Currently, all SGLT2 inhibitors approved for treating T2DM are all C-glucosides such as dapagliflozin (approximately 1200-fold selectivity for SGLT2 versus SGLT1), canagliflozin (∼155-fold selectivity for SGLT2 over SGLT1), empagliflozin (∼2600-fold selectivity for SGLT2 over SGLT1), and sotagliflozin (∼20-fold selectivity for SGLT2 over SGLT1).